2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 88
- 主要终点
- relapse
研究概览
简要总结
patients with refractory /relapsed lymphoma received high-dose etoposide for hematopoietic stem cell (HSC) mobilization.All patients received high-dose etoposide 20-25 mg/kg/d intravenously for two consecutive days followed by rhG-CSF10ug/kg/day subcutaneously at 48 hours after chemotherapy; rhG-CSF was continued until the end of harvesting for HSCs/HPCs. Peripheral blood counts were performed daily for all patients following the initiating of rhG-CSF. Leukapheresis was performed when peripheral blood white blood count exceeded 4×109/L with blood cell The harvested cells reached at least 2*108/kg for mononuclear cells and/or 2*106/kg for CD34+ cells with once to twice leukapheresis. The final product was kept frozen in liquid nitrogen.Auto-PBSCT
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 16 Years 至 60 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •relapsed/refractory lymphoma ,siut APBSCT
排除标准
- •bone marrow without involvement by lymphoma cells
研究组 & 干预措施
Disease status at mobilization PR
干预措施: high-dose etoposide (Drug)
Disease status at mobilization PD
干预措施: high-dose etoposide (Drug)
结局指标
主要结局
relapse
时间窗: 10 years
relapse
death
时间窗: 10 years
death
CR
时间窗: 10 years
Complete response
次要结局
未报告次要终点
研究者
Yang Jun
Principal Investigator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
